FAQ

  • Minister of Health Regulation 10 of 2021 concerning the Implementation of Vaccination in the Context of Combating the Corona Virus Disease 2019 (Covid-19) Pandemic
  • Decree of the Minister of Health of the Republic of Indonesia Number hk.01.07/menkes/4627/2021 regarding the appointment of PT Bio Farma (Persero) in the Implementation of the Procurement of the Corona Virus Disease 2019 (Covid-19) Vaccine for the Implementation of Mutual Cooperation Vaccination

Vaksinasi Gotong Royong is the implementation of Vaccination for employees, families and other related individuals in the family whose funding is borne or charged to legal entities/business entities.

Financing is borne by Legal Entities or Business Entities and may not collect vaccination fees from employees or families.

Can not. Companies that have an obligation to make payments. Funding for the Gotong Royong vaccination is borne by the Legal Entity/Business Entity that will implement the Gotong Royong vaccine for employees, families and individuals related to the family.

Participate in the Vaksin Gotong Royong Program to accelerate Indonesia’s economic recovery and to accelerate the formation of herd immunity, among others by preparing data on the Gotong Royong vaccination target accompanied by data on the number, name, and address (by name and by address), as well as the population identification number and following the next process in accordance with the Technical Guidelines for Vaccination Implementation. in the context of dealing with the corona virus disease 2019 (Covid-19) pandemic

In accordance with PMK 10 of 2021, the vaccines used must be different, meaning they are not the same, and have received approval for use in an emergency period (emergency use authorization), or the issuance of a distribution permit number from the National Food and Drug Agency (NFDA) in accordance with the provisions of the legislation

Yes, foreign nationals can participate in the Vaksin Gotong Royong.

Everyone who has been designated as the target recipient of theVaccine COVID-19 based on data collection is required to take part in the COVID-19 Vaccination in accordance with the provisions of the legislation.

Ministry of Health of the Republic of Indonesia through Bio Farma based on :

  • The red zone is according to data from the Ministry of Health (Historical distribution of vaccines in the Java-Bali area 70%; outside Java 30%).
  • The type of company. Types of companies that support economic growth, are needed by the community & work-intensive ways, contact with many people (risk of transmission).
  • Readiness of 50% DP payment and full payment before the vaccine is sent to Health Facilities.

currently it is not possible because the availability of vaccines is limited.

Sinopharm Vaccine

for each time the injection is made, the company will be charged a fee of IDR 164.334,-

The first injection was given on 18 May 2021

No. Health Service Facilities (Fasyankes) that can carry out Vaksin Gotong Royong services are Health Facilities that are not implementing the Vaccination Program

The implementation of Vaksin Gotong Royong is carried out through cooperation between legal entities/business entities and Bio Farma. Furthermore, vaccination services are carried out at public/private health care facilities. If a legal entity/business entity has a Health Service Facility that meets the requirements, then the Vaksin Gotong Royong service can be carried out at the Health Service Facility concerned. In carrying out the Vaksin Gotong Royong service, health facilities must coordinate with the district/city health office.

Indonesian Health Ministry

It can’t. The cost of Vaksin Gotong Royong services carried out by public/private Health Service Facilities may not exceed the maximum rate that has been set by the Minister of Health in .PMK 10 of 202

legal entities/business entities can only purchase their products provided that the legal entity/business entity has its own health service facilities that meet the requirements

  • have health personnel implementing COVID-19 Vaccination;
  • have a cold chain facility in accordance with the type of COVID-19 Vaccine used or in accordance with the provisions of the legislation; and
  • has an operational permit for Health Service Facilities or is determined by the Minister in accordance with the provisions of the legislation.

Technical Instructions for the Implementation of Vaccination in the Context of Handling the Corona Virus Disease 2019 (Covid-19) Pandemic issued by the Ministry of Health, among others, regulate service standards, and standard procedures etc.

Everyone who has been given the COVID-19 Vaccination is given a COVID-19 Vaccination card or electronic certificate

PT Bio Farma as a State-Owned Enterprise was appointed in the Implementation of the Corona Virus Disease 2019 (COVID-19) Vaccine Procurement for the Vaksin Gotong Royong Program.

  • carry out the procurement of the Corona Virus Disease 2019 (COVID-19) vaccine for the implementation of Vaksin Gotong Royong in accordance with the provisions of the legislation;
  • submit data and information needed for the implementation of audit/supervision; and
  • submit periodic reports to the Minister through the Director General of Pharmaceuticals and Medical Devices regarding the procurement process and realization

Total vaccine is 7,500,000 (seven million five hundred thousand) doses.

Assist in the registration of Vaksin Gotong Royong needs for legal entities/private business entities and report it to PT Bio Farma to be forwarded to the Ministry of Health of the Republic of Indonesia

With PT Bio Farma

It Can’t.

Yes, Needed

Yes, Needed

No Need

No need. Cooperation Agreements are only made one by the center.

Yes they can.

The implementation of Gotong Royong vaccination can be carried out by the Company’s health facilities with the terms and conditions in accordance with the Technical Instructions for Vaccination Implementation in the Context of Combating the Corona Virus Disease 2019 (Covid-19) Pandemic.

Vaccine booster or follow – up vaccine is COVID – 19 Vaccine for anyone that already has a complete primary vaccine dose to improve immunity and extend protection period. Now follow – up COVID – 19 vaccine or vaccine booster is provided by the government.

Vaccine booster or follow – up vaccine is COVID – 19 Vaccine for anyone that already has a complete primary vaccine dose to improve immunity and extend protection period. Now follow – up COVID – 19 vaccine or vaccine booster is provided by the government.

18 Years old or older citizen and this will be prioritized for elders and immunocompromised patients

  1. There is a tendency of immunity to decrease after 6 months of vaccination, especially now many new COVID – 19 variants that are emerging include omicron. Refer to meta analysis study and regression analysis by Fekin et al. in 2021, there’s found out if four COVID – 19 vaccine effectiveness that has Emergency Use Listing (EUL) from World Health Organization (WHO) will decrease up to 8 percent in 6 month for all age groups. At the same period for people aged 50 years and older, vaccine effectiveness will decrease 10 percent and 32 percent to reduce symptoms emergence
  2. As an effort to increase people’s adaptability in COVID-19 era for increasing citizen’s health for a long period of time.
  3. Vaccine booster to fulfill everybody’s right in getting vaccine for personal and community protection
  1. Vaccine recipients need to show their Identity Number (NIK) in KTP (Kartu Tanda Penduduk) or through Peduli Lindungi application
  2. Aged 18 years and older; and
  3. Already has complete primary vaccine dose at least for 6 months
  1. Homologous, is a follow – up vaccine (booster) injection by using same vaccine type with the primary dose vaccine type that already injected before
  2. Heterologous, is a follow – up vaccine (booster) injection by using different vaccine type with the primary dose vaccine type that already injected before

Based on the letter from the Directorate General of Disease Prevention & Control of the Ministry of Health number SR.02.06/C/1641/2022 regarding the addition of the Sinopharm COVID-19 Vaccination Regiment as a Continued Dose (Booster)

Indonesian POM agency has issued an Emergency Use Authorization (EUA) permit for the Sinopharm vaccine as a homologous booster on January 27, 2022 which is intended for Sinopharm primary vaccination participants and on March 10, 2022 has issued a heterologous EUA booster intended for Sinovac primary vaccination participants so that people who After receiving the primary dose of the Covid-19 vaccine, Sinopharm or Sinovac can re-register through the Mutual Cooperation Vaccination program.

The Implementation of Mutual Cooperation Vaccination is the implementation of vaccinations for employees, families and related families/employees who receive both Sinopharm and Sinovac primary vaccines which are intended to re-increase immunity against Covid-19. The provisions for the Sinopharm booster vaccination are as follows:

  • Age 18 years and over
  • It has reached 3 months after the second dose of Sinopharm/Sinovac primer primary immunization

The administration is 1 (one) dose / full dose.

In accordance with the direction of the Indonesian Ministry of Health through a letter from the Director General of P2P of the Ministry of Health No. SR.02.06/II/455/2022 regarding the Provision of the Sinopharm COVID-19 Vaccine as a Booster for the Mutual Cooperation Vaccine dated February 2, 2022, the implementation of the Sinopharm booster can follow the Mutual Cooperation Vaccine mechanism in accordance with applicable regulations (Minister of Health Decree No. HK.01.07 /MENKES/6424/2021 concerning Technical Guidelines for Vaccination Implementation in the context of Combating the COVID-19 Pandemic) until the issuance of new regulations.

So that the implementation of the Sinopharm booster vaccination can be given by legal entities or business entities to employees, families and those involved in the family/employees, whose funding is borne/charged by legal entities or business entities.

  • Vaccine price per dose is IDR 164.334,-
  • Service price is IDR 117.910,-
  • Price of Booster Vaccine (1 dose) IDR 164.334,-
  • Primary Vaccine Price (2x) IDR 328.668,-

Decree of the Minister of Health of the Republic of Indonesia No. HK.01.07/MENKES/4643/2021 about Sinopharm Vaccine Pricing through appointment from PT BIo Farma (Persero) in COVID – 19 Vaccine procurement and maximum service price for Vaksinasi Gotong Royong implementation.

1. Efficacy

  • Has 78% efficacy as primary vaccine for Sinopharm
  • increased immune response 8 – 8.4 x as homologous booster vaccine and increased immune response 10.65 x as heterologous booster vaccine
  • The Sinopharm vaccine is broad spectrum and can protect against the SARS nCoV2
  • Can be used for ages 18 – 59 years as well as pregnant and lactating women

2. Maintaining Employee Productivity
Vaccination can be carried out at the workplace (on-site) or at the clinic (walk-in) on weekdays because it does not cause significant Post Immunization Adverse Events (AEFI).

3. Speed and Flexibility of Vaccination Implementation

  • The implementation can be done at any time because the vaccine is already available at 350 Kimia Farma clinics
  • Companies can choose between 760 health facilities spread throughout Indonesia according to the distribution of company employees

4. Vaccine Certificate
The booster vaccine certificate can be obtained immediately after vaccination through the Peduli Protect application.

5. News Coverage / Exposure
Companies that participate in the Sinopharm Booster Vaccine program have the opportunity to be covered in digital media regarding the company’s support for the success of the government vaccination program launched by the government.